PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018
LYON, France and CAMBRIDGE, Mass., July  17, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq: ERYP ) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were
View HTML
Toggle Summary ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
(GLOBE NEWSWIRE via COMTEX) --- Focuses development efforts on solid tumor indications - Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer.
View HTML
Toggle Summary ERYTECH to Present at JMP Securities Life Science Conference
LYON, France , June 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil
View HTML
Toggle Summary ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
LYON, France , June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on
View HTML
Toggle Summary General Meeting to be held on June 28, 2018 and Availability of Related Materials
LYON, France , June 07, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018
LYON, France , June 04, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic
View HTML
Toggle Summary ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference
LYON, France --(BUSINESS WIRE)--May 30, 2018-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive
View HTML
Toggle Summary ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, May 15 th at 2:30 pm CET / 8:30 am EDT Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3 Selected triple-negative breast cancer as the next solid tumor indication;
View HTML
Toggle Summary ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy
LYON, France , May 14, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice
View HTML
Toggle Summary ERYTECH to Host First Quarter 2018 Conference Call and Business Update
LYON, France , May 09, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first
View HTML
Top